Group items tagged

Established in 2005, the New York Stem Cell Foundation is dedicated to curing major contemporary diseases through stem cell research. In addition to performing and conducting original research, the foundation acts as an international hub for thinkers, laboratories, and institutions working to maximize impact for actual patients. To that end, the foundation is accepting applications from early-career investigators working to advance the understanding and use of stem cells in the development of treatments for human disease. The RFA is open to national and international researchers based at an accredited academic or nonprofit research institution.

The Advancing Informal STEM Learning program invests in research and development of innovative and field-advancing out-of-school STEM learning and emerging STEM learning environments. 

With this DCL, ECR invites proposals on the development, application, and extension of formal models and methodologies for STEM education research and evaluation, including methods for improving statistical modeling, qualitative modeling, measurement, replication, and learning analytics. This includes research on methodological aspects of new or existing procedures for data collection, curation, and inference in STEM education. Similarly, ECR seeks proposals related to collection of unique databases with cross-boundary value, particularly when paired with innovative developments in measurement or methodology (standard statistical modeling, qualitative research, measurement, replication and learning analytics). Proposers must demonstrate how advances in the methodology will support important theoretical insights in STEM education research or evaluation. Proposers are encouraged to explore a wide range of fundamental research projects (in the areas of quantitative, qualitative, measurement, replication, and learning analytics methodologies)

Nicotine is a substance that occurs naturally in tobacco leaves. American Blend cigarettes use three different types of tobacco ranging in nicotine content:  (1) Flue-cured tobacco with leaf ranging from 15 to 45 mg/g and stem from 3 to 7 mg/g, (2) Burley tobacco with leaf ranging from 15 to 50 mg/g and stem from 3 to 7 mg/g, and (3) Oriental tobacco with leaf ranging from 5 to 20 mg/g (this type is not stemmed).  Given these ranges and common blending approaches, the nicotine content in most American Blend cigarettes ranges from 14 to 27 mg/g. There exists the possibility that future governmental regulations will require a significant reduction in the concentration of nicotine in tobacco products. Existing extraction technologies can reduce the amount of nicotine by 90% but are very expensive, or they eliminate the sensorial characteristics and flavor compounds of tobacco as well. NineSigma's client desires a cost-effective technology to significantly lower levels of nicotine in tobacco leaves by 50% or more.

The Presidential Awards for Excellence in Science, Mathematics, and Engineering Mentoring (PAESMEM) is a Presidential award established by the White House in 1995. The purpose of the award is to recognize U.S. citizens or permanent residents and U.S. organizations that have demonstrated excellence in mentoring individuals from groups that are underrepresented in science, technology, engineering, and mathematics (STEM) education and workforce. Groups that are underrepresented in STEM include women, people with disabilities, underrepresented racial and ethnic minorities, as well as individuals from low socio-economic backgrounds and some geographic regions such as urban and rural areas. The PAESMEM program is administered by the National Science Foundation (NSF) on behalf of the White House Office of Science and Technology Policy (OSTP). Nominations, including self-nominations, are invited for Individual and Organizational PAESMEM awards. Individuals and organizations in all public and private sectors are eligible including industry, academia, primary and secondary education, military and government, non-profit organizations, and foundations. Nominations are encouraged from all geographical regions in the U.S., its territories or possessions, particularly jurisdictions designated by Congress under NSF's Experimental Program to Stimulate Competitive Research (EPSCoR).

The National Workforce Diversity Pipeline Program (NWDP) seeks to address health disparities among racial and ethnic minorities by supporting networks of institutions focused on, and with demonstrated commitment and capacity to establish pipeline programs to increase minority and disadvantaged students' (Appendix A) awareness of and pursuit in the areas of health care and behavioral health and increase the availability of STEM education programs.

The purpose of the Funding Opportunity Announcement (FOA) is to encourage research into the role of pluripotent progenitor/stem cells in the pathogenesis and treatment of selected gynecologic disorders, specifically uterine fibroids, endometriosis, adenomyosis, endometrial polyps, and pelvic organ prolapse.

The purpose of this FOA is to invite: 1) descriptive studies to identify putative juvenile protective factors, 2) experimental studies to test hypotheses about their effects on aging and 3) translational studies to characterize potential beneficial and adverse effects of maintaining or modulating the level of juvenile protective factors in adult life. Juvenile protective factors (JPFs), intrinsic to an immature organism, help to maintain or enhance certain physiological functions across all or some stages of postnatal development (i.e., segment of the life span between birth and sexual maturity), but diminish or disappear as the organism transitions from one maturational stage to the next. The loss or diminution of JPFs after a given stage of postnatal development or at time of sexual maturity may contribute to the onset of deleterious aging changes (e.g., compromised stem cell function and reparative capacity) across adulthood. This FOA is uniquely focused on animal and clinical studies which involve comparisons between juvenile versus adult states or between stages of postnatal development to identify putative JPFs and their effects on aging. 

The Verizon Foundation's primary philanthropic focus areas are: Healthcare for children, women and seniors; STEM education for K-12 youth and Energy Management. Grant applications are by invitation only and are reviewed from February 3, 2014 through midnight on October 10, 2014. Please contact your local Verizon Community Relations Manager to learn more.

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative involves an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HIV-associated neurological disorders (HAND) in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines.

This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HAND in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIGMS R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To this end, this funding opportunity announcement (FOA) encourages the development of innovative educational activities for pre-kindergarten to grade 12 (P-12), pre-service and in-service teachers (Teachers) and students from underserved communities with a focus on Courses for Skills Development, Research Experiences, Mentoring Activities, Curriculum or Methods Development and Outreach. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Information on current SEPA projects can be found at: https://www.nigms.nih.gov/Research/crcb/sepa/Pages/default.aspx and http://nihsepa.org. Applicants are strongly encouraged to consult with the SEPA Scientific/Research Contact to be advised on the appropriateness of the intended P-12 STEM or ISE project for SEPA program objectives and the priorities of the NIGMS.

To advance the understanding and treatment of myelodysplastic syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal hematopoiesis of indeterminate potential (CHIP)), the Vera and Joseph Dresner Foundation established the MDS Research Fund (MDSRF) to continue the work that Joseph Dresner initiated with a gift to establish the Joseph Dresner Family Clinic for Hematologic Malignancies & Stem Cell Transplantation at the Karmanos Cancer Institute. The fund is committed to expanding the foundation's investments in support of cutting-edge MDS research and related programs that will lead to future standards of care - and, ultimately, a cure - by facilitating the advancement of innovative basic, translational, or clinical research

Despite clear progress made during the last 15 years on cellular transplantation for T1D, the most recent results demonstrate a long term limited viability of engrafted islets and, as a result, limited insulin independence under different novel modalities of immunosuppressive (IS) regimens tested.  In addition, even the most innovative IS regimens required for transplant survival still have significant immediate side effects and long-term safety is uncertain. These problems together with the scarcity of donor organs and the complexity of transplants mandates a renewed emphasis on the investigation of novel methods within the field of tissue engineering for the development of a bio-artificial, cell-based hormone replacement therapy that may minimize the need of IS. To support this, it is necessary to develop/optimize novel/smart/safe biomaterials, scaffolds, bio-matrices and bio-barriers that may protect grafted cells from immune rejection and simultaneously promote appropriate vascularization/innervation with an efficient exchange of nutrients to optimize cellular long-term survival and proper function.  It is also necessary to investigate methods to use different cell sources including human progenitor cells and induced pluripotent stem cells as a valid option for cell replacement therapy. 

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen. Also listed under R21

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

What we will consider funding: Innovative ideas for improving measurement of coverage and equity data for use by program staff and managers. Specifically, their ability to collect and deliver the right data at the right time to the appropriate audiences would benefit from: Incorporating advances in technology to support decision makers in planning and executing program strategies Integration of immunization data systems, as well as the ability to address data use demands from multiple stakeholders. Enabling a culture that supports data quality and use e.g. provides feedback on data at multiple levels. Alignment of incentives to promote reporting of accurate data above coverage estimates. Innovations in process efficiency toward improved service delivery. These may stem from lean healthcare, or other approaches, but should have the end goal of improving the experience of healthcare workers, caregivers, or both.

The Office of Research on Womens Health (ORWH) announces the availability of administrative supplements to support interdisciplinary, transdisciplinary and multidisciplinary research focused on the effect of sex/gender influences at the intersection of a number of social determinants, including but not limited to: race/ethnicity, socioeconomic status, education, health literacy and other social determinants in human health and illness. This research includes preclinical, clinical and behavioral studies with the specific purpose to provide Administrative Supplements to active NIH parent grants for one year to address health disparities among women of populations in the US who are understudied, underrepresented and underreported in biomedical research. The proposed research must address an area specified within Objective 3.9 (Goal 3.0) of the NIH Strategic Plan for Research on Womens Health which states: Examine health disparities among women stemming from differences in such factors as race and ethnicity, socioeconomic status, gender identity, and urban-rural living, as they influence health, health behaviors, and access to screening and therapeutic interventions. Projects must include a focus on one or more NIH-designated health disparities populations, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities (SGM). Combinations of one or more populations is also encouraged, e.g. socioeconomically disadvantaged sexual and gender minorities.

The purpose of this FOA is to encourage applications that seek to conduct studies of the visual system. This FOA will support applications that either Those that involve human subjects, but are not NIH-defined clinical trials (see NOT-OD-15-015); or Those that are NIH-defined clinical trials and are designed to address either: 1) mechanisms underlying human vision in health and disease; or 2) interventions that entail procedures with minimal risk to subjects. A mechanistic trial is defined as "A study designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. "Minimal risk" means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. NIH-defined clinical trial applications that are neither mechanistic nor minimal risk are not eligible for this FOA. Large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials are not appropriate for this FOA. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.